Overview

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

Status:
Completed
Trial end date:
2015-09-28
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences